C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
02/08/2024 15:22
* C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show
a
fall in quarterly revenue when it reports results on October 30
(estimated) for the period ending September 30 2024
* The Watertown Massachusetts-based company is expected to
report
a 58.5% decrease in revenue to $4.6 million from $11.07 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for C4 Therapeutics Inc is
for a
loss of 38 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 25.2%
in the last three months.
* Wall Street's median 12-month price target for C4
Therapeutics
Inc is $14.00, above its last closing price of $6.68.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.37 -0.37 -0.26 Beat 30
Mar. 31 2024 -0.36 -0.35 -0.41 Missed -16.7
Dec. 31 2023 -0.64 -0.68 -0.70 Missed -2.6
Sep. 30 2023 -0.67 -0.66 -0.52 Beat 21.2
Jun. -0.69 -0.69 -0.73 Missed -6.1
30 2023
Mar. 31 2023 -0.73 -0.75 -0.71 Beat 4.8
Dec. 31 2022 -0.73 -0.74 -0.77 Missed -3.5
Jan. 1 0001 -0.65 -0.67 -0.65 Beat 3
This summary was machine generated August 2 at 14:22 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)